Vol 14, No 3 (2018)
Guidelines / Expert consensus
Published online: 2018-03-13
Skin carcinomas
DOI: 10.5603/OCP.2018.0019
Oncol Clin Pract 2018;14(3):129-147.
Abstract
Not available
References
- Basal Cell and Squamous Cell Skin Cancer wersja 1.2018. www.nccn.org (2018).
- Trakatelli M, Morton C, Nagore E, et al. BCC subcommittee of the Guidelines Committee of the European Dermatology Forum. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014; 24(3): 312–329.
- Bonerandi JJ, Beauvillain C, Caquant L, et al. French Dermatology Recommendations Association (aRED). Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol. 2011; 25 Suppl 5: 1–51.
- Bath FJ, Bong J, Perkins W, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2003(2): CD003412.
- Bath-Hextall FJ, Matin RN, Wilkinson D, et al. Interventions for cutaneous Bowen's disease. Cochrane Database Syst Rev. 2013(6): CD007281.
- Clark CM, Furniss M, Mackay-Wiggan JM. Basal cell carcinoma: an evidence-based treatment update. Am J Clin Dermatol. 2014; 15(3): 197–216.
- Marghoob AM, Malvehy J, Braun RP. Atlas of dermoscopy. Second edition. Informa healthcare 2012.
- Argenziano G, Zalaudek I, Giacomel J. Preface. Dermoscopy. Dermatol Clin. 2013; 31(4): XIII–XIV.
- Berking C, Hauschild A, Kölbl O, et al. Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int. 2014; 111(22): 389–395.
- Krajowy Rejestr Nowotworów. www.onkologia.org.pl.
- Bologni JL, Jorizzo JL, Schaffer JV. Dermatology. Elsevier Saunders 2012.
- Nawrocka A, Owczarek W. Zasady diagnostyki u pacjentów z nowotworem skóry. Chirurgia Po Dyplomie 2014 sierpień.
- Rutkowski P, Jassem J, Krzakowski M. Złośliwe nowotwory skóry. Via Medica, Gdańsk 2014.
- Werner RN, Stockfleth E, Connolly SM, et al. International League of Dermatological Societies, European Dermatology Forum. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol. 2015; 29(11): 2069–2079.
- Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017; 31 Suppl 2: 5–7.
- Garrett GL, Yuan JT, Shin TM, et al. Transplant Skin Cancer Network (TSCN. Validity of skin cancer malignancy reporting to the Organ Procurement Transplant Network: A cohort study. J Am Acad Dermatol. 2018; 78(2): 264–269.
- Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. JAMA Dermatol. 2014; 150(12): 1281–1288.
- Owczarek W, Rutkowski P, Słowińska M, et al. Zalecenia dotyczące leczenia raka podstawnokomórkowego i raka kolczystokomórkowego przygotowane przez Sekcję Onkologiczną Polskiego Towarzystwa Dermatologicznego i Sekcję Akademia Czerniaka Polskiego Towarzystwa Chirurgii Onkologicznej. Onkol Prakt Klin Edu. 2015; 1(2): 96–106.
- Gupta AK, Paquet M, Villanueva E, et al. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012; 12: CD004415.
- McGillis ST, Fein H. Topical treatment strategies for non-melanoma skin cancer and precursor lesions. Semin Cutan Med Surg. 2004; 23(3): 174–183.
- Hansen EK, Roach M. Handbook of evidence-based radiation oncology (2nded.). Springer, New York 2010.
- Hernández-Machin B, Borrego L, Gil-García M, et al. Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int J Dermatol. 2007; 46(5): 453–459.
- Rowe DE, Carroll RJ, Day CLJr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989; 15(3): 315–328.
- Rowe DE, Carroll RJ, Day CLJr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. Dermatol Surg Oncol. J Dermatol Surg Oncol. 1989; 15(4): 424–431.
- Rowe D, Carroll R, Day C. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol. 1992; 26(6): 976–990.
- Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997; 76(1): 100–106.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2017.
- Fort M, Guet S, Colson-Durand L, et al. Role of radiation therapy in non-melanoma cancers, lymphomas and sarcomas of the skin: Systematic review and best practice in 2016. Crit Rev Oncol Hematol. 2016; 99: 200–213.
- Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst. 1996; 88(24): 1848–1853.
- Lichter M. Therapeutic Ionizing Radiation and the Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma. Arch Dermatol. 2000; 136(8): 1007–1011.
- Perkins JL, Liu Y, Mitby PA, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2005; 23(16): 3733–3741.
- Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366(23): 2171–2179.
- Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015; 16(6): 729–736.
- Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012; 366(23): 2180–2188.
- Erdem GU, Sendur MA, Ozdemir NY, et al. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma. Curr Med Res Opin. 2015; 31(4): 743–756.
- Peris K, Licitra L, Ascierto PA, et al. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future Oncol. 2015; 11(4): 703–712.
- Proctor AE, Thompson LA, O'Bryant CL. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother. 2014; 48(1): 99–106.
- Dreno B, Basset-Seguin N, Caro I, et al. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist. 2014; 19(8): 790–796.
- Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2017 [Epub ahead of print].
- Lipson EJ, Lilo MT, Ogurtsova A, et al. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer. 2017; 5: 23.
- Ikeda S, Goodman AM, Cohen PR, et al. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1.
- Stevenson ML, Wang CQF, Abikhair M, et al. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. JAMA Dermatol. 2017; 153(4): 299–303.
- Ran X, Yang K. Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives. Drug Des Devel Ther. 2017; 11: 2007–2014.
- Nagasaka M, Zaki M, Kim H, et al. PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. J Immunother Cancer. 2016; 4: 83.
- Tran DC, Colevas AD, Chang AL. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2017; 153(1): 92–94.
- Ran X, Yang K. Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives. Drug Des Devel Ther. 2017; 11: 2007–2014.
- Hauschild A, Eichstaedt J, Möbus L, et al. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. Eur J Cancer. 2017; 77: 84–87.
- Arits AH, Mosterd K, Essers BAb, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013; 14(7): 647–654.
- Basset-Seguin N, Bissonnette R, Girard C, et al. Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. J Eur Acad Dermatol Venereol. 2014; 28(5): 626–632.
- Lehmann P. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol. 2007; 156(5): 793–801.
- Wan MT, Lin JY. Current evidence and applications of photodynamic therapy in dermatology. Clin Cosmet Investig Dermatol. 2014; 7: 145–163.
- Ortiz-Policarpio B, Lui H. Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers. Skin Therapy Lett. 2009; 14(6): 1–3.
- Choudhury K, Volkmer B, Greinert R, et al. Effectiveness of skin cancer screening programmes. Br J Dermatol. 2012; 167 Suppl 2: 94–98.
- Toker C, Kroll MH, Toker C, et al. Trabecular carcinoma of the skin. Arch Dermatol. 1972; 105(1): 107–110.
- De Wolff-Peeters C, Marien K, Mebis J, et al. A cutaneous APUDoma or Merkel cell tumor? A morphologically recognizable tumor with a biological and histological malignant aspect in contrast with its clinical behavior. Cancer. 1980; 46(8): 1810–1816, doi: 10.1002/1097-0142(19801015)46:8<1810::aid-cncr2820460819>3.0.co;2-7.
- Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003; 49(5): 832–841.
- Reichgelt BA, Visser O. Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993-2007. Eur J Cancer. 2011; 47(4): 579–585.
- Albores-Saavedra J, Batich K, Chable-Montero F, et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010; 37(1): 20–27.
- Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev. 1999; 8(2): 153–158.
- Lunder EJ, Stern RS. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med. 1998; 339(17): 1247–1248.
- Engels EA, Frisch M, Goedert JJ, et al. Merkel cell carcinoma and HIV infection. Lancet. 2002; 359(9305): 497–498.
- Penn I, First MR. Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation. 1999; 68(11): 1717–1721.
- Koljonen V, Kukko H, Tukiainen E, et al. Incidence of Merkel cell carcinoma in renal transplant recipients. Nephrol Dial Transplant. 2009; 24(10): 3231–3235.
- Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008; 319(5866): 1096–1100.
- Kassem A, Schöpflin A, Diaz C, et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res. 2008; 68(13): 5009–5013.
- Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008; 58(3): 375–381.
- Allen P, Zhang ZF, Coit D. Surgical management of Merkel cell carcinoma. Ann Surg. 1999; 229(1): 97–105.
- Merkel Cell Carcinoma. NCCN Guidelines. Version 1. 2018.
- Harms KL, Healy MA, Nghiem P, et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol. 2016; 23(11): 3564–3571.
- Oram CW, Bartus CL, Purcell SM. Merkel cell carcinoma: a review. Cutis. 2016; 97(4): 290–295.
- Lebbe C, Becker JC, Grob JJ, et al. European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015; 51(16): 2396–2403.
- Gupta SG, Wang LC, Peñas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol. 2006; 142(6): 685–690.
- Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005; 23(10): 2300–2309.
- Strom T, Carr M, Zager JS, et al. Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Ann Surg Oncol. 2016; 23(11): 3572–3578.
- Garneski KM, Nghiem P. Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol. 2007; 57(1): 166–169.
- Poulsen M, Rischin D, Walpole E, et al. Trans-Tasman Radiation Oncology Group. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. J Clin Oncol. 2003; 21(23): 4371–4376.
- Poulsen MG, Rischin D, Porter I, et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys. 2006; 64(1): 114–119.
- Schadendorf D, Lebbé C, Zur Hausen A, et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017; 71: 53–69.
- Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016; 17(10): 1374–1385.
- Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016; 374(26): 2542–2552.
- Medina-Franco H, Urist MM, Fiveash J, et al. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol. 2001; 8(3): 204–208.
- Nijhawan N, Ross MI, Diba R, et al. Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Ophthal Plast Reconstr Surg. 2004; 20(4): 291–295.
- Shields JA, Demirci H, Marr BP, et al. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005; 50(2): 103–122.
- Song A, Carter KD, Syed NA, et al. Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes. Ophthal Plast Reconstr Surg. 2008; 24(3): 194–200.
- Nelson B, Hamlet K, Gillard M, et al. Sebaceous carcinoma. J Am Acad Dermatol. 1995; 33(1): 1–15.
- Mehta NJ, Torno R, Sorra T. Extramammary Pagetʼs Disease. South Med J. 2000; 93(7): 713–715.
- Pucevich B, Catinchi-Jaime S, Ho J, et al. Invasive primary ductal apocrine adenocarcinoma of axilla: a case report with immunohistochemical profiling and a review of literature. Dermatol Online J. 2008; 14(6): 5.
- Paties C, Taccagni GL, Papotti M, et al. Apocrine carcinoma of the skin. A clinicopathologic, immunocytochemical, and ultrastructural study. Cancer. 1993; 71(2): 375–381, doi: 10.1002/1097-0142(19930115)71:2<375::aid-cncr2820710218>3.0.co;2-4.
- Chiller K, Passaro D, Scheuller M, et al. Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome. Arch Dermatol. 2000; 136(11): 1355–1359.
- Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma. A clinicopathologic study of 35 cases. Arch Dermatol. 1983; 119(2): 104–114.
- Yeung KY, Stinson JC. Mucinous (adenocystic) carcinoma of sweat glands with widespread metastasis. Case report with ultrastructural study. Cancer. 1977; 39(6): 2556–2562, doi: 10.1002/1097-0142(197706)39:6<2556::aid-cncr2820390637>3.0.co;2-d.